{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:55:00Z","timestamp":1790848500182,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate and compare the risk of diabetic retinopathy and kidney disease between once\u2010daily liraglutide and once\u2010weekly dulaglutide in Japanese participants with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      A total of 341 participants newly initiated on once\u2010daily liraglutide 0.9\u2009mg or once\u2010weekly dulaglutide 0.75\u2009mg between 2015 and 2020 were included in this study. We used propensity score\u2010based inverse probability of treatment weighting to adjust for baseline characteristics between the two groups. The participants were divided into three cohorts according to retinopathy, albuminuria, and glomerular filtration rate (GFR). The primary outcomes were the incidence or progression of diabetic retinopathy or kidney disease (albuminuria or reduced estimated GFR (eGFR) &lt;60\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ). The incidence rate and risk of outcomes were compared between the two groups using Poisson regression and Cox proportional hazard models. [Correction added on September 7, 2026, after first online publication: The total number of participants in the Materials and Methods section has been corrected from 331 to 341.]\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a mean follow\u2010up of 4.4 and 3.6\u2009years in the liraglutide and dulaglutide groups, respectively, there were no differences between the two groups in terms of the risk of incidence of retinopathy and reduced GFR (hazard ratio (HR): 0.98 [0.60\u20131.60] and 0.82 [0.36\u20131.84]). Dulaglutide showed a lower incidence or progression rate but similar risk of albuminuria compared to liraglutide (54.7 vs 25.8 per 1,000 person\u2010years (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04), HR: 0.51 [0.25\u20131.05]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study showed that once\u2010daily liraglutide and once\u2010weekly dulaglutide have similar risks for retinopathy, albuminuria, and reduced GFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdi.70407","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:24:33Z","timestamp":1784964273000},"page":"1726-1734","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2258-6094","authenticated-orcid":false,"given":"Aki","family":"Katamine","sequence":"first","affiliation":[{"name":"Division of Diabetes and Endocrinology Sasebo Central Hospital  Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-2606","authenticated-orcid":false,"given":"Junko","family":"Oya","sequence":"additional","affiliation":[{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4793-8352","authenticated-orcid":false,"given":"Yuichiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-8382","authenticated-orcid":false,"given":"Yukiko","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-7212","authenticated-orcid":false,"given":"Tomoko","family":"Nakagami","sequence":"additional","affiliation":[{"name":"Division of Diabetology and Metabolism, Department of Internal Medicine Tokyo Women's Medical University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-2280"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13128"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.017"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12602"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04149-z"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(94)90246-1"},{"key":"e_1_2_9_14_1","first-page":"1985","article-title":"The National Glycohemoglobin Standardization Program: A five\u2010year progress report","volume":"47","author":"Little RR","year":"2001","journal-title":"Clin Chem"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00671.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12902"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0213-3"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/db15-0443"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.7.874"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13877"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30125-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12793"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0172-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.427"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000094334"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1824"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.06.009"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.70407","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:05:52Z","timestamp":1790845552000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.70407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/jdi.70407"],"URL":"https:\/\/doi.org\/10.1111\/jdi.70407","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"2026-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}